NASDAQ:BIVI BioVie Q3 2025 Earnings Report $1.07 -0.08 (-6.96%) As of 04:00 PM Eastern Earnings HistoryForecast BioVie EPS ResultsActual EPS-$0.15Consensus EPS -$0.32Beat/MissBeat by +$0.17One Year Ago EPSN/ABioVie Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABioVie Announcement DetailsQuarterQ3 2025Date5/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsBioVie's Q3 2025 earnings is scheduled for Tuesday, May 13, 2025Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) BioVie Earnings HeadlinesBioVie (BIVI) Projected to Post Earnings on TuesdayMay 12 at 1:47 AM | americanbankingnews.comBIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmApril 30, 2025 | globenewswire.comMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…May 13, 2025 | Crypto Swap Profits (Ad)BioVie initiates SUNRISE-PD trial assessing BezisterimApril 17, 2025 | markets.businessinsider.comBioVie, Inc.: BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient EnrolledApril 16, 2025 | finanznachrichten.deBioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient EnrolledApril 16, 2025 | markets.businessinsider.comSee More BioVie Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioVie and other key companies, straight to your email. Email Address About BioVieBioVie (NASDAQ:BIVI), a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.View BioVie ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Upcoming Earnings Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)Applied Materials (5/15/2025)Copart (5/15/2025)NetEase (5/15/2025)Alibaba Group (5/15/2025)Deere & Company (5/15/2025)Mizuho Financial Group (5/15/2025)National Grid (5/15/2025)Walmart (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
